JP2019512535A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512535A5
JP2019512535A5 JP2018551351A JP2018551351A JP2019512535A5 JP 2019512535 A5 JP2019512535 A5 JP 2019512535A5 JP 2018551351 A JP2018551351 A JP 2018551351A JP 2018551351 A JP2018551351 A JP 2018551351A JP 2019512535 A5 JP2019512535 A5 JP 2019512535A5
Authority
JP
Japan
Prior art keywords
disorders
compound
alkyl
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018551351A
Other languages
English (en)
Japanese (ja)
Other versions
JP6968092B2 (ja
JP2019512535A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/057765 external-priority patent/WO2017167993A1/en
Publication of JP2019512535A publication Critical patent/JP2019512535A/ja
Publication of JP2019512535A5 publication Critical patent/JP2019512535A5/ja
Application granted granted Critical
Publication of JP6968092B2 publication Critical patent/JP6968092B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018551351A 2016-04-01 2017-03-31 Tnf活性のモジュレーターとしての縮合五環式イミダゾール誘導体 Active JP6968092B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16163571.9 2016-04-01
EP16163571 2016-04-01
PCT/EP2017/057765 WO2017167993A1 (en) 2016-04-01 2017-03-31 Fused pentacyclic imidazole derivatives as modulators of tnf activity

Publications (3)

Publication Number Publication Date
JP2019512535A JP2019512535A (ja) 2019-05-16
JP2019512535A5 true JP2019512535A5 (enExample) 2020-04-23
JP6968092B2 JP6968092B2 (ja) 2021-11-17

Family

ID=55650321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018551351A Active JP6968092B2 (ja) 2016-04-01 2017-03-31 Tnf活性のモジュレーターとしての縮合五環式イミダゾール誘導体

Country Status (8)

Country Link
US (1) US10669286B2 (enExample)
EP (1) EP3436459B1 (enExample)
JP (1) JP6968092B2 (enExample)
CN (1) CN109195969B (enExample)
BR (1) BR112018069936A2 (enExample)
CA (1) CA3019026A1 (enExample)
EA (1) EA201892153A1 (enExample)
WO (1) WO2017167993A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
BR112018001960A2 (pt) 2015-08-03 2018-09-18 Bristol-Myers Squibb Company compostos heterocíclicos úteis como moduladores de tnf alfa
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
CN108948034B (zh) * 2018-06-05 2019-09-13 河南大学 一种色满桥环异吲哚酮及其制备方法
PT3870586T (pt) * 2018-10-24 2023-07-19 UCB Biopharma SRL Derivados de imidazole pentacíclico fundido como moduladores da atividade do tnf
WO2024129763A1 (en) * 2022-12-13 2024-06-20 Forward Therapeutics, Inc. MODULATORS OF TNF-α ACTIVITY
US20260028348A1 (en) * 2023-01-05 2026-01-29 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2024251282A1 (zh) * 2023-06-09 2024-12-12 上海翰森生物医药科技有限公司 五环类衍生物抑制剂、其制备方法和应用
TW202521544A (zh) 2023-08-16 2025-06-01 美商雷瑟拉股份有限公司 TNFα活性調節劑及其用途
TW202547476A (zh) 2024-04-03 2025-12-16 美商弗沃德醫療公司 TNF-α活性調節劑
WO2025218735A1 (zh) * 2024-04-17 2025-10-23 上海翰森生物医药科技有限公司 五环类衍生物抑制剂、其制备方法和应用
WO2025255096A1 (en) * 2024-06-03 2025-12-11 Dana-Farber Cancer Institute, Inc. Cycloalkyl and heterocyclic modulators of tnf activity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2517281A1 (en) 2003-03-10 2004-10-14 Pfizer Inc. Phosphate/sulfate ester compounds and pharmaceutical compositions for inhibiting protein interacting nima (pin1)
TW200615273A (en) * 2004-11-10 2006-05-16 Nicholas Piramal India Ltd Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
EP2721026B1 (en) 2011-06-20 2016-03-02 Vertex Pharmaceuticals Incorporated Phosphate esters of gyrase and topoisomerase inhibitors
US9550737B2 (en) 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
BR112015000675B1 (pt) 2012-07-13 2022-07-12 UCB Biopharma SRL Derivados de imidazopiridina como moduladores da atividade de tnf
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
GB201321730D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN107108672B (zh) 2014-10-03 2019-11-08 Ucb生物制药私人有限公司 稠合的五环咪唑衍生物

Similar Documents

Publication Publication Date Title
JP2019512535A5 (enExample)
JP2019512533A5 (enExample)
JP2014513139A5 (enExample)
JP2017531648A5 (enExample)
JP2016040288A5 (enExample)
JP2014513110A5 (enExample)
JP2018501315A5 (enExample)
JP2014139226A5 (enExample)
JP2013510124A5 (enExample)
JP2016525075A5 (enExample)
JP2014525420A5 (enExample)
JP2015143283A5 (enExample)
JP2014513140A5 (enExample)
ME02203B (me) Hinolin i hinoksalin derivati kao inhibitori kinaza
JP2013529611A5 (enExample)
JP2012525431A5 (enExample)
HRP20201094T1 (hr) IMIDAZO[1,2-a]PIRIDINI, NAMIJENJENI LIJEČENJU ILI SPRJEČAVANJU HIPERURIKEMIJE ILI GIHTA
JP2016525076A5 (enExample)
JP2016523270A5 (enExample)
JP2016522232A5 (enExample)
JP2016515582A5 (enExample)
JP2017532360A5 (enExample)
JP2013540712A5 (enExample)
JP2016520118A5 (enExample)
JP2014510147A5 (enExample)